RecruitingPhase 2NCT07293403

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

A Phase II Study of Duvelisib Maintenance After First-Line Therapy for Peripheral T-Cell Lymphoma

Sponsor

City of Hope Medical Center

Enrollment

25 participants

Start Date

Jun 7, 2026

Study Type

INTERVENTIONAL

Conditions

Peripheral T-Cell Lymphoma, Not Otherwise Specified Follicular Helper T-Cell Lymphoma

Summary

This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell lymphomas. Duvelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Biospecimen Collection, a procedure called Bone Marrow Aspiration, and others for people with follicular helper t-cell lymphoma and peripheral t-cell lymphoma, not otherwise specified. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.